vs

Side-by-side financial comparison of EXACT SCIENCES CORP (EXAS) and SERVICE CORP INTERNATIONAL (SCI). Click either name above to swap in a different company.

SERVICE CORP INTERNATIONAL is the larger business by last-quarter revenue ($1.1B vs $878.4M, roughly 1.3× EXACT SCIENCES CORP). SERVICE CORP INTERNATIONAL runs the higher net margin — 14.3% vs -9.8%, a 24.1% gap on every dollar of revenue. On growth, EXACT SCIENCES CORP posted the faster year-over-year revenue change (23.1% vs 1.7%). EXACT SCIENCES CORP produced more free cash flow last quarter ($120.4M vs $87.2M). Over the past eight quarters, EXACT SCIENCES CORP's revenue compounded faster (17.4% CAGR vs 3.1%).

Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.

International Distribution Services Limited is a British company providing postal and courier services. IDS was created in 2013 by the UK government as a new holding company of Royal Mail, and a majority of its shares were then sold on the London Stock Exchange, with the government initially retaining a 30 per cent at the time. As of April 2025, IDS is owned and operated by Czech-based EP Group, owned by Daniel Křetínský.

EXAS vs SCI — Head-to-Head

Bigger by revenue
SCI
SCI
1.3× larger
SCI
$1.1B
$878.4M
EXAS
Growing faster (revenue YoY)
EXAS
EXAS
+21.4% gap
EXAS
23.1%
1.7%
SCI
Higher net margin
SCI
SCI
24.1% more per $
SCI
14.3%
-9.8%
EXAS
More free cash flow
EXAS
EXAS
$33.2M more FCF
EXAS
$120.4M
$87.2M
SCI
Faster 2-yr revenue CAGR
EXAS
EXAS
Annualised
EXAS
17.4%
3.1%
SCI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EXAS
EXAS
SCI
SCI
Revenue
$878.4M
$1.1B
Net Profit
$-86.0M
$159.4M
Gross Margin
70.1%
28.0%
Operating Margin
-9.4%
24.8%
Net Margin
-9.8%
14.3%
Revenue YoY
23.1%
1.7%
Net Profit YoY
90.1%
5.3%
EPS (diluted)
$-0.45
$1.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EXAS
EXAS
SCI
SCI
Q4 25
$878.4M
$1.1B
Q3 25
$850.7M
$1.1B
Q2 25
$811.1M
$1.1B
Q1 25
$706.8M
$1.1B
Q4 24
$713.4M
$1.1B
Q3 24
$708.7M
$1.0B
Q2 24
$699.3M
$1.0B
Q1 24
$637.5M
$1.0B
Net Profit
EXAS
EXAS
SCI
SCI
Q4 25
$-86.0M
$159.4M
Q3 25
$-19.6M
$117.5M
Q2 25
$-1.2M
$122.9M
Q1 25
$-101.2M
$142.9M
Q4 24
$-864.6M
$151.4M
Q3 24
$-38.2M
$117.8M
Q2 24
$-15.8M
$118.2M
Q1 24
$-110.2M
$131.3M
Gross Margin
EXAS
EXAS
SCI
SCI
Q4 25
70.1%
28.0%
Q3 25
68.6%
25.1%
Q2 25
69.3%
25.5%
Q1 25
70.8%
27.1%
Q4 24
69.0%
28.0%
Q3 24
69.4%
24.9%
Q2 24
69.8%
24.9%
Q1 24
70.0%
26.2%
Operating Margin
EXAS
EXAS
SCI
SCI
Q4 25
-9.4%
24.8%
Q3 25
-3.0%
21.4%
Q2 25
-0.3%
21.1%
Q1 25
-13.6%
23.4%
Q4 24
-122.8%
24.0%
Q3 24
-5.6%
20.9%
Q2 24
-3.8%
21.4%
Q1 24
-16.7%
22.2%
Net Margin
EXAS
EXAS
SCI
SCI
Q4 25
-9.8%
14.3%
Q3 25
-2.3%
11.1%
Q2 25
-0.1%
11.5%
Q1 25
-14.3%
13.3%
Q4 24
-121.2%
13.8%
Q3 24
-5.4%
11.6%
Q2 24
-2.3%
11.4%
Q1 24
-17.3%
12.6%
EPS (diluted)
EXAS
EXAS
SCI
SCI
Q4 25
$-0.45
$1.13
Q3 25
$-0.10
$0.83
Q2 25
$-0.01
$0.86
Q1 25
$-0.54
$0.98
Q4 24
$-4.69
$1.02
Q3 24
$-0.21
$0.81
Q2 24
$-0.09
$0.81
Q1 24
$-0.60
$0.89

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EXAS
EXAS
SCI
SCI
Cash + ST InvestmentsLiquidity on hand
$964.7M
$243.6M
Total DebtLower is stronger
$5.1B
Stockholders' EquityBook value
$2.4B
$1.6B
Total Assets
$5.9B
$18.7B
Debt / EquityLower = less leverage
3.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EXAS
EXAS
SCI
SCI
Q4 25
$964.7M
$243.6M
Q3 25
$1.0B
$241.3M
Q2 25
$858.4M
$255.4M
Q1 25
$786.2M
$227.2M
Q4 24
$1.0B
$218.8M
Q3 24
$1.0B
$185.4M
Q2 24
$946.8M
$184.4M
Q1 24
$652.1M
$205.6M
Total Debt
EXAS
EXAS
SCI
SCI
Q4 25
$5.1B
Q3 25
$5.0B
Q2 25
$5.0B
Q1 25
$4.7B
Q4 24
$4.8B
Q3 24
$4.7B
Q2 24
$4.7B
Q1 24
$4.6B
Stockholders' Equity
EXAS
EXAS
SCI
SCI
Q4 25
$2.4B
$1.6B
Q3 25
$2.5B
$1.6B
Q2 25
$2.5B
$1.6B
Q1 25
$2.4B
$1.7B
Q4 24
$2.4B
$1.7B
Q3 24
$3.2B
$1.6B
Q2 24
$3.2B
$1.5B
Q1 24
$3.1B
$1.6B
Total Assets
EXAS
EXAS
SCI
SCI
Q4 25
$5.9B
$18.7B
Q3 25
$5.9B
$18.4B
Q2 25
$5.8B
$18.0B
Q1 25
$5.7B
$17.3B
Q4 24
$5.9B
$17.4B
Q3 24
$6.7B
$17.4B
Q2 24
$6.7B
$16.8B
Q1 24
$6.4B
$16.7B
Debt / Equity
EXAS
EXAS
SCI
SCI
Q4 25
3.10×
Q3 25
3.17×
Q2 25
3.19×
Q1 25
2.87×
Q4 24
2.83×
Q3 24
2.92×
Q2 24
3.05×
Q1 24
2.90×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EXAS
EXAS
SCI
SCI
Operating Cash FlowLast quarter
$151.7M
$212.9M
Free Cash FlowOCF − Capex
$120.4M
$87.2M
FCF MarginFCF / Revenue
13.7%
7.8%
Capex IntensityCapex / Revenue
3.6%
11.3%
Cash ConversionOCF / Net Profit
1.34×
TTM Free Cash FlowTrailing 4 quarters
$356.8M
$554.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EXAS
EXAS
SCI
SCI
Q4 25
$151.7M
$212.9M
Q3 25
$219.9M
$252.3M
Q2 25
$89.0M
$166.4M
Q1 25
$30.8M
$311.1M
Q4 24
$47.1M
$264.1M
Q3 24
$138.7M
$263.8M
Q2 24
$107.1M
$196.9M
Q1 24
$-82.3M
$220.1M
Free Cash Flow
EXAS
EXAS
SCI
SCI
Q4 25
$120.4M
$87.2M
Q3 25
$190.0M
$150.7M
Q2 25
$46.7M
$83.4M
Q1 25
$-365.0K
$233.0M
Q4 24
$10.7M
$151.8M
Q3 24
$112.6M
$162.8M
Q2 24
$71.2M
$100.8M
Q1 24
$-120.0M
$140.3M
FCF Margin
EXAS
EXAS
SCI
SCI
Q4 25
13.7%
7.8%
Q3 25
22.3%
14.2%
Q2 25
5.8%
7.8%
Q1 25
-0.1%
21.7%
Q4 24
1.5%
13.9%
Q3 24
15.9%
16.1%
Q2 24
10.2%
9.7%
Q1 24
-18.8%
13.4%
Capex Intensity
EXAS
EXAS
SCI
SCI
Q4 25
3.6%
11.3%
Q3 25
3.5%
9.6%
Q2 25
5.2%
7.8%
Q1 25
4.4%
7.3%
Q4 24
5.1%
10.3%
Q3 24
3.7%
10.0%
Q2 24
5.1%
9.3%
Q1 24
5.9%
7.6%
Cash Conversion
EXAS
EXAS
SCI
SCI
Q4 25
1.34×
Q3 25
2.15×
Q2 25
1.35×
Q1 25
2.18×
Q4 24
1.75×
Q3 24
2.24×
Q2 24
1.67×
Q1 24
1.68×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EXAS
EXAS

Screening$695.1M79%
Precision Oncology$183.2M21%

SCI
SCI

Cemetery$510.9M46%
Funeral Matured Preneed Revenue$196.5M18%
Cemetery Recognized Preneed Merchandise And Service Revenue$107.4M10%
Cemetery Atneed Revenue$104.9M9%
CA$56.4M5%
Funeral Other Revenue$54.6M5%
Cemetery Other Revenue$40.2M4%
Nonfuneral Home Revenue$28.1M3%
Non Funeral Home Preneed Sales Revenue$22.0M2%

Related Comparisons